Caricamento...
Targeted Therapies: The Rare Cancer Paradigm
This review analyzes the state of the art of targeted therapies for several tumors, starting from the paradigmatic example of Imatinib treatment in chronic myelogenous leukemia (CML). We discuss how rare tumors can be models for various mechanisms of receptor tyrosine kinase (RTK) activation, and pr...
Salvato in:
| Pubblicato in: | Mol Oncol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2009
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5527958/ https://ncbi.nlm.nih.gov/pubmed/19913465 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2009.10.003 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|